Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva in Myelodysplastic Syndrome
NCT00570375Phase 2Withdrawn
- Sponsor
- University of Cincinnati
- Start
- Nov 2007
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by University of Cincinnati. Planned start Nov 2007; status: withdrawn.
02
Drugs
erlotinib
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00570375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570375.